Li N, Xiong R, He R, Liu B, Wang B, & Geng Q. (2021). Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation. Dove Medical Press.
Chicago Style (17th ed.) CitationLi N, Xiong R, He R, Liu B, Wang B, and Geng Q. Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation. Dove Medical Press, 2021.
MLA (9th ed.) CitationLi N, et al. Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.